Background: IL-10 is an anti-inflammatory cytokine required for intestinal immune homeostasis. It mediates suppression of Tcell responses by type 1 regulatory T (T R 1) cells but is also produced by CD25 1 regulatory T (Treg) cells. Objective: We aimed to identify and characterize human intestinal T R 1 cells and to investigate whether they are a relevant cellular source of IL-10 in patients with inflammatory bowel diseases (IBDs). Methods: CD4
1 T cells isolated from the intestinal lamina propria of human subjects and mice were analyzed for phenotype, cytokine production, and suppressive capacities. Intracellular IL-10 expression by CD4
1 T-cell subsets in the inflamed guts of patients with IBD (Crohn disease or ulcerative colitis) was compared with that in cells from noninflamed control subjects. Finally, the effects of proinflammatory cytokines on T-cell IL-10 expression were analyzed, and IL-1b and IL-23 responsiveness was assessed. Results: Intestinal T R 1 cells could be identified by coexpression of CCR5 and programmed cell death protein 1 (PD-1) in human subjects and mice. CCR5 IL-10 is an anti-inflammatory cytokine that plays a nonredundant role in maintaining intestinal immune homeostasis. 1, 2 IL-10-deficient mice and patients with genetic defects in the IL-10/IL-10 receptor pathway experience spontaneous intestinal inflammation and colitis in the presence of a normal gut microflora. [3] [4] [5] Experiments with conditional knockout mice indicated that the protective IL-10 is produced by T cells, 6 and studies with IL-10 receptor-deficient immune cells suggested that intestinal macrophages and T H 17 cells are directly controlled by IL-10. [7] [8] [9] [10] [11] However, several T-cell subsets can produce IL-10, and the relevant cellular source of IL-10 in patients with inflammatory bowel diseases (IBDs) remained unclear.
Type 1 regulatory T (T R 1) cells are characterized by high IL-10-producing capacities and the ability to inhibit T-cell responses and colitis in an IL-10-dependent manner. 10, [12] [13] [14] [15] [16] [17] They produce variable levels of IFN-g and are distinct from conventional regulatory T (Treg) cells, which are defined by expression of CD25 and forkhead box p3 (Foxp3). Nevertheless, CD25 Treg cells can produce IL-10, which is important for their suppressive functions at barrier organs, including the gut. 7, 17 T R 1 cells are less defined then Foxp3
1 Treg cells, but they can be induced under a variety of conditions in vitro. [18] [19] [20] Notably, in vitro-generated T R 1 cells are being tested currently for their therapeutic potential to treat different immune-mediated diseases, including Crohn disease (CD). [21] [22] [23] However, in vitrogenerated T R 1 cells are likely to differ from in vivo-occurring T R 1 cells. Previously, we identified in vivo-occurring Foxp3 
CD25
2 IL-7 receptor (IL-7R) 2 T cells in human blood. 24 These T R 1 cells are also present in tonsils, where they regulate B-cell responses. 25 In mice in vivo-occurring T R 1 cells coexpress lymphocyte-activation gene 3 (LAG3) and CD49b and accumulate in the small intestine in an anti-CD3-induced, self-limiting colitis model. 26 Conversely, the characteristics of intestinal T R 1 cells in human subjects and their role in patients with IBDs remain to be defined. 24, 26 In particular, whether T R 1 cells have reduced anti-inflammatory functions in the intestines of patients with IBD is unknown.
Here we show that intestinal IFN-g-and IL-10-producing T R 1 cells can be identified by CCR5 and programmed cell death protein 1 (PD-1) coexpression in human subjects and mice. These T R 1 cells were IL-23 responsive, downregulated IL-10 with IL1b and IL-23, and had reduced IL-10-producing capacities in the intestines of patients with IBDs, suggesting that proinflammatory cytokines inhibit their anti-inflammatory functions in patients with IBDs.
METHODS

Human samples
Buffy coat blood from healthy donors and surgically removed intestinal specimens from patients were obtained from the IRCCS Policlinico Ospedale Maggiore, Milan, Italy. Intestinal specimens were obtained from biopsy specimens or from patients with IBD undergoing therapeutic resection of highly inflamed parts of the intestine (Table E1 ). The intestinal mucosa was excised from the intestines of patients with CD and ulcerative colitis (UC) at the time of surgery. As a noninflamed control, intestinal samples were obtained from healthy tissue (at least 7 cm away from neoplastic tissue) of patients undergoing surgery for colorectal cancer (CRC; Table  E1 ). As additional noninflamed controls, biopsy specimens from 3 patients presenting for gastroesophageal reflux-related symptoms were used. The mucosal layer was separated from the rest of the tissue by a pathologist and directly transferred to our laboratory. The ethics committee approved the use of specimens for research purposes (permission no. 2476), and biopsy specimens (protocol IISR-2014-100922) and informed consent were obtained from patients. 
Cell isolation
Human subjects. PBMCs and intestinal lamina propria mononuclear cells were isolated by means of Ficoll-Hypaque gradient, according to published protocols. 27 Lymphocyte subsets were purified by means of cell sorting on a FACSAria (BD, Franklin Lakes, NJ) based on surface marker expression (purity >95%). Thus T R 1 cells were sorted as CD4 1 Mice. For isolation of lamina propria cells from the mouse, small intestines were collected, Peyer patches were removed, and tissue pieces were incubated with 1.5 mmol/L EDTA and 1 mmol/L dithiothreitol at 378C for 15 minutes, followed by mechanical disaggregation with the gentleMACS dissociator. Cells were then separated further with a Percoll gradient. Cells were isolated from the duodenums and jejunums of anti-CD3-treated mice. J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 5 (REA351; Miltenyi Biotec, Bergisch Gladbach, Germany); phosphorylated signal transducer and activator of transcription (STAT) 3 (4/P-STAT3; BD), CD45RA (MEM-56; ImmunoTools, Friesoythe, Germany), and CD1c (AD5-8E7; Miltenyi Biotec). T-cell cytokine production was measured after stimulation with 0.1 mmol/L phorbol 12-myristate 13-acetate (PMA) and 1 mg/mL ionomycin (Sigma-Aldrich, St Louis, Mo) in the presence of 10 mg/ mL Brefeldin A (Sigma); cells were fixed, permeabilized, stained, and analyzed by means of flow cytometry. For IL-10 and IFN-g production of CD4 1 T-cell subsets, lymphocytes were gated according to CD4, IL-7R, CD25, CCR5, and PD-1 expression (see Fig E1) .
IL-7R
Mice. 
Colonoscopies were performed in blind fashion by using the Coloview system. In brief, the colitis score was based on the granularity of mucosal surfaces, stool consistency, vascular pattern, translucency of the colon, and visible fibrin (0-3 points for each). Histologic examinations were performed according to standard methods on hematoxylin and eosin staining of paraffinembedded small intestinal and colonic specimens.
Suppression assays
Human subjects. 
T-cell culture
Purified human T R 1, Treg, and IL-7R 1 T H cells were stimulated in 96-well plates precoated with anti-CD3 and anti-CD28 antibodies at 2 mg/mL and 1000 U/mL IL-2 in the absence or presence of recombinant IL-1b and IL-23 at 10 ng/mL. After 72 hours, cells were detached from the plates and transferred to uncoated wells. After another 3 days of culture, they were tested for IL-10 and IFN-g production after brief stimulation with PMA and ionomycin, as described above. The assay to measure IL-23 responsiveness was described previously. 28 Briefly, cells were washed extensively and incubated in the absence or presence of IL-23, and phospho(Y)-STAT3 measured by means of intracellular staining and flow cytometry. In the case of intestinal T R 1 cells, IL-23 receptor (IL-23R) was assessed by using RT-PCR, as previously described. 28 
Statistics
Statistical significance was calculated by using the 2-tailed Student t test in case of Gaussian distribution; otherwise, the Mann-Whitney test for unmatched or Wilcoxon for paired groups. In the case of multiple comparisons, 1-way ANOVA with the Tukey posttest was used.
RESULTS
Human intestinal T R 1 cells that coexpress IL-10 and IFN-g can be identified by CCR5 and PD-1 expression
We first investigated whether human T cells with T R 1-like characteristics, as we previously identified in peripheral blood 24 and tonsils, 25 were also present in nonlymphoid tissues, such as the intestinal lamina propria. The large majority of CD4 1 T cells in the noninflamed intestinal lamina propria obtained from patients with CRC had an IL-7R hi CD25
low helper phenotype, and only a small fraction expressed IL-10 on ex vivo stimulation with PMA and ionomycin, as detected by means of intracellular staining (Fig 1, A) . A minor population of CD4 1 CD25
2
IL-7R
2 T cells could also be detected in the lamina propria, and a significantly higher fraction of these effector-like cells expressed IL-10 (Fig 1, A , and see Fig E1, A and B) . In addition, CD25
Treg cells were present at low frequencies in the intestinal lamina propria, and they also contained a significant fraction of cells that could express IL-10 on stimulation. Consistent with these results, high amounts of IL-10 protein were detected in culture supernatants of FACS-purified, intestinal CD25 with PMA and ionomycin, whereas only low amounts were measured in supernatants of IL-7R hi CD25 low T H cells (see Fig  E1, C) . In contrast to T R 1 cells, the majority of CD25 1 IL-7R low T cells expressed Foxp3 (Fig 1, B) , indicating that they represented conventional CD25 
2 T cells coexpressed IFN-g (Fig 1, C) , whereas IL-10 1 CD25 1 Treg cells did not.
The large majority of IL-10
2 T cells expressed CCR5 and PD-1 (Fig 2, A) , whereas CCR6 was largely absent (data not shown). These surface markers allowed strong enrichment for IL-10 1 T cells in the intestine (Fig 2, B) . Moreover, purified intestinal CCR5 
2 T R 1 cells secreted significantly higher amounts of IL-10 protein compared with CCR5 2
2 control T cells (see Fig E1, C) .
1 Treg cells (Fig 2, C) .
2 control cells that lacked CCR5 expression did not suppress T-cell proliferation (Fig 2, C) , which is consistent with their low IL-10 expression (Fig 2, A , and see Fig E1, C) . Finally, when we compared frequencies of CD4
2
CCR5
1 T R 1 cells among total CD4 1 T cells in peripheral blood and the noninflamed intestinal lamina propria of patients with CRC, we found that T R 1 cells were strongly enriched in the gut (Fig 2, D) .
LAG3 is expressed by T R 1 cells in human subjects and mice. 26, 29 Only a small fraction of human CD4
IL-7R
2
CCR5
1 T R 1 cells (1.6% 6 1.4%, n 5 10) showed LAG3 surface expression (see Fig E3, A, in this article's Online Repository at www.jacionline.org). However, we found that human CD4
1
CD25
2
IL-7R
2
CCR5
1 T R 1 cells, which did not express LAG3 at the cell surface, nevertheless expressed LAG3 mRNA (see Fig E3, B) 
1 T R 1 cells efficiently upregulated LAG3 protein expression at the cell surface after T-cell receptor stimulation in vitro (see Fig E3, C) .
Intestinal murine CCR5
1 PD-1 1 T R 1 cells suppress transfer colitis
We next investigated CCR5 and PD-1 expression on intestinal T R 1 cells in mice and the in vivo-suppressive capacities of intestinal T R 1 cells that coexpressed CCR5 and PD-1. Intestinal T R 1 cells can be tracked in IL-10 and Foxp3 double-reporter (FirxTiger) mice 26, 30 after repetitive anti-CD3 injections, a treatment that induces self-limiting colitis. As observed in human subjects, the large majority of intestinal IL-10 eGFP1
Foxp3
RFP2 T R 1 cells coexpressed CCR5 and PD-1 (Fig 3, A) , and they also coexpressed LAG3 and CD49b on the cell surface, as expected. 26 Consistent with high expression of the IL-10 egfp reporter, purified murine CCR5 
PD-1
1 T R 1 cells also secreted substantial amounts of IFN-g but little IL-17 (Fig 3,  B) . Consistently, they did not express CCR6 (data not shown), which is characteristic for T H 17 cells 31, 32 but not for human IL-7R 2 T R 1 cells. 25 Finally, IL-10-producing CCR5 (Fig 3, C) , confirming that they represent T R 1 cells.
Intestinal T R 1 cells suppress T H 17 cells in an IL-10-dependent manner in vivo and inhibit colitis. 10 To assess the in vivo-suppressive capacities of CCR5
1 PD-1 1 T R 1 cells, we transferred in vitro-generated T H 17 cells (CD4 1 Foxp3 RFP2 IL-17 eGFP1 ) into Rag1 2/2 mice in the presence or absence of purified intestinal T R 1 cells. Transfer of T H 17 cells caused disease in the intestine, as assessed based on the colitis score and by means of histologic evaluation (Fig 3, D and E) . Cotransfer of IL-10 eGFP1 CCR5 1 PD-1 1 T R 1 cells strongly inhibited colitis induction, whereas IL-10 eGFP1 control T cells that lacked CCR5 and PD-1 were also suppressive but less potent (Fig 3, D and E) .
IL-10 and IFN-g-coexpressing T R 1 cells downregulate IL-10 production in the inflamed guts of patients with IBD and with IL-1b plus IL-23 in vitro
Because intestinal CCR5
1 T R 1 cells inhibited transfer colitis in mice, we asked whether they could also play a protective role in patients with IBDs. We first analyzed whether numbers of CCR5 
IL-7R
2 T R 1 cells or CD25 1 Treg cells were reduced in the intestinal lamina propria of patients (Table E1) with CD or UC, the 2 principal forms of IBD, compared with the noninflamed lamina propria obtained from control subjects with CRC. We observed a moderate increase in numbers of CD25
1 Treg cells in the lamina propria of patients with UC and of CCR5
1 IL-7R 2 T R 1 cells in patients with CD, which did not reach statistical significance (Fig 4, A) . Notably, there was also no significant difference between the frequencies of these Treg cell subsets in inflamed and noninflamed biopsy specimens from the same patients with IBD (see Fig E5 in 
org). Intestinal IL-7R
2 T R 1 cells had markedly reduced capacities to express IL-10 in patients with both types of IBD, whereas IL-10 expression by CD25
1 Treg cells and IL-7R hi T H cells was not significantly altered (Fig 4, B) . Interestingly, T R 1 cells that coexpressed IL-10 and IFN-g were much more strongly affected than those that expressed IL-10 alone, and consequently, only numbers of IFN-g and IL-10-coexpressing T R 1 cells were significantly reduced (Fig 4, C) .
To understand why T R 1 cells downregulated IL-10 production in the intestines of patients with IBDs, we activated circulating IL-7R
2
CCR5
1 T R 1, CD25 1 Treg, and IL-7R hi T H cells in the presence of the proinflammatory cytokines IL-1b and IL-23, which play critical pathogenic roles in colitis. [33] [34] [35] [36] [37] [38] [39] [40] Only T R 1 cells had reduced capacities to express IL-10 after culture with IL-1b and IL-23 ( Fig 5, A and B) . Furthermore, as observed in the intestines of patients with IBDs, the effect was selective for IL-10 and IFN-g-coexpressing T R 1 cells (Fig 5, C) . Conversely, no significant effect on IL-10 was detected in CD25
1 Treg or IL-7R hi T H cells, either in total IL-10 1 cells (Fig 5, B) or in IFN-g-expressing subsets (see Fig E6, A, in this article's Online Repository at www. jacionline.org). This was also true when the fold increase was calculated to eliminate the variability of IL-10 production between different subjects (see Fig E6, B) . Interestingly, neither addition nor neutralization of TNF-a, an efficient therapy for IBD, had a clear effect on IL-10 production (data not shown).
To understand whether the selective effect of IL-1b and IL-23 on IL-10 production by T R 1 cells might be caused by a different responsiveness to these proinflammatory cytokines, we assessed IL-1 receptor (IL-1R) surface expression and IL-23-induced STAT3 activation. Activated CD25 1 Treg cells expressed high levels of IL-1R1 and IL-1R2, whereas T R 1 cells and T H cells expressed these receptors only at low levels (Fig 5, D) , arguing against a critical role for IL-1b in reduced IL-10 production by T R 1 cells. However, IL-23 efficiently induced STAT3 phosphorylation in activated T R 1 cells (Fig 5, E , and see Fig E7 in this article's Online Repository at www.jacionline.org), whereas IL-23 responsiveness was lower in IL-7R
1 T H and CD25 1 Treg cells, although the latter tendency did not reach statistical significance (P 5 .088).
To control whether intestinal T R 1 cells could respond to IL-23, we purified T R 1 cells from the lamina propria of patients with IBDs and quantified IL-23R mRNA expression (Fig 5, F) . Notably, IL-23R expression is efficiently induced on naive T cells by T H 17-promoting cytokines 28 and is expressed together with CCR6 on T H 17 cells, 31, 41, 42 particularly in the gut. 43 Therefore we compared IL-23R mRNA expression of intestinal T R 1 cells with that of intestinal CCR6
CD25
2 T H 17 cells as a positive control. IL-23R mRNA was detectable in all cases in both intestinal T-cell subsets. Interestingly, T R 1 and T H 17 cells expressed similar levels of IL-23R mRNA in patients with UC, whereas T R 1 cells expressed even higher levels in patients with CD (Fig 5, E) . Intestinal T R 1 cells were negative for IL-7R, CD25, and CCR6, distinguishing them from helper T cells, Foxp3
1 Treg cells, 44 and T H 17/T H 22 cells, 31 respectively. However, they expressed the T H 1-associated chemokine receptor CCR5, which allows immune cells to enter nonlymphoid tissues. Indeed, T R 1 cells produced high amounts of IFN-g and were enriched in the gut. In addition, they also express PD-1, an inhibitory receptor that directly induces IL-10 in T cells 45 and inhibits DC maturation. 46 PD-1 expression on T R 1 cells is consistent with the notion that they are chronically activated cells. 24, 47, 48 In vivo-occurring T R 1 cells also express LAG3, 26, 29 an inhibitory receptor that binds MHC class II, and we found that both human and mouse CCR5 1 T R 1 cells expressed LAG3. However, the large majority of human CCR5
1 IL-7R -T R 1 cells expressed LAG3 on the cell surface only after T-cell receptor stimulation. These data suggest a possible heterogeneity among T R 1 cells, which could result from different stages of activation, maturation, and/or function. This aspect is currently under investigation. In any case, for the first time, the phenotype reported here has allowed identification and isolation of T R 1 cells that produce high levels of IL-10 and IFN-g directly in the human gut.
IL-10 produced by T cells has a nonredundant role in preventing excessive inflammation in response to the gut microbiota. 49 Both Foxp3 1 Treg and Foxp3 2 T R 1 cells were identified as possible relevant sources of IL-10 in experimental colitis in mice, 9, 10, 12 but the contributions of these 2 Treg cell subsets in human IBDs is very difficult to address and therefore largely unknown. Our data point to a critical role of IL-10 and IFNg-coproducing T R 1 cells in patients with IBDs because only this T-cell population showed reduced IL-10 expression in the intestinal lamina propria of patients with IBDs. Reduced IL-10 expression by T R 1 cells was detected in both patients with UC and those with CD, indicating that it is a common feature of IBDs. Of note, murine T R 1 cells control colitogenic T H 17 cells and macrophages in an IL-10-dependent manner in vivo, [7] [8] [9] [10] [11] and human IL-10 and IFN-g-coexpressing IL-7R 2 T R 1 cells suppress T-cell responses through IL-10. 24 Preliminary doseresponse experiments with anti-CD3-and anti-CD28-coated beads and autologous peripheral CD4
1 T cells as responder cells (data not shown) suggested that intestinal T R 1 and CD25
1 Treg cells had similar suppressive potential and that both subsets could suppress T-cell activation directly.
A caveat of the present study is that we used the healthy lamina propria of patients with CRC as a noninflamed control, as do many studies on human intestinal immune cells given the difficulty to analyze the gut of healthy subjects. It is possible that the presence of intestinal tumors or the increased age of patients with CRC influences the properties of intestinal Treg cells. However, the similar frequencies of T-cell subsets at inflamed and noninflamed sites of the same patients with IBD and the similar IL-10 expression among CD4 1 T cells from noninflamed biopsy specimens of a few patients with gastrointestinal reflux (data not shown) compared with intestinal CD4 1 T cells from patients with CRC suggest that these factors did not have a major effect on these analyzed parameters.
Interestingly, in non-immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome autoimmune enteropathy caused by dysfunctional Foxp3
1 Treg cells, we observed enhanced IL-10 production of CD4 1 T cells, suggesting that T R 1 cells were not defective. In addition, we observed uncon- 
purified ex vivo from intestinal specimens of patients with CD (squares) and patients with UC (circles).
Each dot represents 1 patient (n 5 4). *P < .05 and **P < .005.
=
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 5 trolled IL-17 production by CD8 1 intraepithelial lymphocytes, which was not observed in patients with CD. 50 These findings are consistent with the view that Foxp3
1 Treg and T R 1 cells have unique functions in the control of intestinal immune homeostasis. The reduced IL-10 production by T R 1 cells could be explained by their responsiveness to IL-23, a highly pathogenic cytokine in patients with colitis. [33] [34] [35] [36] [37] [38] IL-1b is another pathogenic cytokine in patients with colitis 39, 40 and inhibits IL-10 production by human T H 17 cells. 51 However, CD25 1 Treg cells that expressed the highest levels of IL-1Rs maintained normal IL-10 production in cultures with IL-1b, suggesting that IL-23 might be the more relevant cytokine to inhibit IL-10 production by Treg cells. IL-23 is thought to render T H 17 cells pathogenic 52, 53 and to inhibit the generation of Foxp3
1 Treg cells from naive precursor cells. 33 Inhibition of IL-10 production by established T R 1 cells is a third mechanism that is likely to be highly relevant in patients with IBDs and is consistent with increased T-cell IL-10 production in IL-23R knockout mice. 38, 54 IL-23R expression is characteristic for T H 17 cells that express CCR6 and secrete IL-17. 42 Therefore it was surprising that IL-7R
2
CCR5
1 T R 1 cells, which lack CCR6 and IL-17 expression, 24, 25 were IL-23 responsive. However, IL-23R expression is directly regulated by the transcription factor T-bet, 55 which also induces IFN-g expression, providing a plausible explanation why selectively IFNg2producing T R 1 cells responded to IL-23 and downregulated IL-10 in the gut. The physiologic function of IL-10 downregulation is probably to allow for a more efficient response against invading intestinal bacteria, but on chronic exposure to these bacteria because of a leaky intestinal barrier, the same mechanism could promote chronic inflammation and colitis. Thus IL-10 production of intestinal T R 1 cells might be a prognostic marker of IBDs. In addition, IL-23 responsiveness is also potentially a novel relevant parameter for T-cell therapy of patients with CD 22 because T R 1 cells that do not respond to IL-23 are expected to maintain IL-10 production and to be thus more efficient to cure colitis. Furthermore, patients with IBDs with low intestinal IL-23 expression might respond better to T R 1 cell therapy. 
